Holen Sie sich die Stockscreener-App
70.49
0.28%
-0.20
Handel nachbörslich:
70.49
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - Insider Monkey
Incyte to present initial data on cancer therapies at ESMO Congress - Investing.com
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 - Yahoo Finance
What analysts say about Incyte Corporation stockFree Buy/Sell Signal Notifications - Autocar Professional
What drives Incyte Corporation stock priceRapid capital growth - Autocar Professional
Is Incyte Corporation a good long term investmentTremendous return rates - jammulinksnews.com
Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Incyte EVP Flannelly sells $83k in shares - Investing.com
Incyte EVP Flannelly sells $83k in shares By Investing.com - Investing.com UK
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
Incyte Announces Q2 2025 Financial Results Call and Webcast Details - MyChesCo
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte stock price target raised to $62 from $61 at UBS on sales outlook - Investing.com Canada
Sun Pharma Shares Climb 3%, Leqselvi Settlement - Rediff
Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S. - The Hindu
Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp - Business Standard
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement - Reuters
Sun Pharma’s baldness drug Leqselvi debuts in US market after patent dispute settled - The Economic Times
Sun Pharma Settles Incyte Corp Litigation - Rediff
India's Sun Pharma launches anti-baldness drug Leqselvi in US - MarketScreener
Sun Pharma settles litigation with Incyte Corp - Press Trust of India
Incyte discloses new bicyclooctane KRAS inhibitors - BioWorld MedTech
Anal Cancer Market Research Report 2025-2035 with Competitive Profiles of Incyte, BioMimetix, Bristol Myers Squibb, and AstraZeneca - Yahoo Finance
Incyte’s Q2 2025 Earnings: What To Expect - Barchart.com
Incyte to Report Second Quarter Financial Results - Business Wire
William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties - Insider Monkey
Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives - MyChesCo
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? - MSN
Incyte: New CEO Brings A New Possible Outcome (NASDAQ:INCY) - Seeking Alpha
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Meury named Incyte CEO as Hoppenot departs - Delaware Business Times
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran” - Insider Monkey
Incyte Corporation (INCY) Announces Leadership Transition with N - GuruFocus
Bill Meury Takes Helm at Incyte (INCY) as New CEO | INCY Stock N - GuruFocus
Incyte Appoints Bill Meury Chief Executive Officer - Contract Pharma
Citi reiterates buy rating on Incyte stock amid CEO transition - Investing.com
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - MSN
How Is Incyte’s Stock Performance Compared To Other Biotech Stocks? - Barchart.com
Incyte stock falls after FDA extends review of pediatric eczema cream - Investing.com
5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call - Yahoo Finance
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis - Business Wire
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Yahoo Finance
Incyte (INCY) Secures FDA Approval for Monjuvi in Follicular Lym - GuruFocus
Incyte wins FDA label expansion for lymphoma drug Monjuvi (INCY) - Seeking Alpha
FDA Approves Incyte's Monjuvi for Follicular Lymphoma Treatment | INCY Stock News - GuruFocus
FDA approves Monjuvi combination therapy for follicular lymphoma By Investing.com - Investing.com Canada
FDA Approves Incyte's (INCY) Tafasitamab-Cxix for Follicular Lym - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in - GuruFocus
Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | I - GuruFocus
Incyte (INCY) Surges on Promising Blood Disorder Treatment Results - GuruFocus
Alopecia Areata Market Expected to Experience Major Growth - openPR.com
QGEN Stock Rises in After Market Following Partnership With Incyte - Yahoo Finance
Incyte stock rating reiterated by Oppenheimer on promising cancer drug data - Investing.com Canada
Jefferies raises Incyte stock price target on promising drug data By Investing.com - Investing.com Canada
3.32%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):